Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Key facts
- Who runs it
- National Cancer Institute (NCI)
- Where
- Ames, Ann Arbor, Appleton, Baker City, Basking Ridge, Belpre, Billings, Boise, Boone, Brighton, Brownstown, Burlington, Caldwell, Canton, Cape Girardeau, Centralia, Charlotte, Chelsea, Chillicothe, City of Saint Peters, Clackamas, Clarkston, Clinton, Clinton Township, Columbus, Commack, Coon Rapids, Coral Gables, Coral Springs, Creve Coeur, Danville, Dearborn, Decatur, Deerfield Beach, Delaware, Detroit, Doral, Dublin, Eau Claire, Edina, Edmonds, Effingham, Farmington Hills, Flint, Fort Dodge, Gahanna, Gastonia, Glens Falls, Goldsboro, Grove City, Harrison, Hollywood, Irvine, Issaquah, Jackson, Jacksonville, Jefferson, La Crosse, Lancaster, Lansing, Lima, Livonia, Mansfield, Marietta, Marion, Marshalltown, Marshfield, Mattoon, Maywood, Meridian, Miami, Middletown, Minneapolis, Minocqua, Monroe, Montvale, Mount Vernon, Nampa, New York, Newark, Newberg, North Miami, Novi, O'Fallon, Ontario, Oregon City, Perrysburg, Plantation, Pontiac, Portland, Portsmouth, Rice Lake, Richmond, Rochester, Saginaw, Saint Joseph, Saint Louis Park, Saint Paul, Seattle, Springfield, St Louis, Stevens Point, Tawas City, Toledo, Tucson, Uniondale, Urbana, Webster, West Bloomfield, Westerville, Weston, Wyandotte, Ypsilanti, and Zanesville, United StatesSee the 150 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 92 people, planned
- Started
- 5 Jan 2022
- Expected to end
- 31 Mar 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Biospecimen Collection
- Bone Marrow Aspiration
- Bone Marrow Biopsy
- Computed Tomography
- Ibrutinib
- Positron Emission Tomography
- Rituximab
- Venetoclax
- Zanubrutinib
- Record updated
- 12 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 34 criteriaShow less
Who can take part
- Participants must have had a confirmed diagnosis of Waldenstrom's macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL). Participants must have measurable disease as determined by IgM protein quantification; IgM Spike: ≥ 500 mg/dL (≥ 5 g/L); Extramedullary disease: The manifestation of a lymphoid mass outside of the bone marrow, resulting in enlargement in extramedullary organs such as the lymph nodes or spleen. Note: all participants must have measurable IgM spike, but are not required to have extramedullary disease
- Testing to establish baseline disease status must be performed within 28 days prior to registration
- Participants must have at least one of the criteria to require therapy for WM including:; Anemia; Thrombocytopenia; Neuropathy related to WM; Symptomatic hyperviscosity or serum viscosity levels ≥ 4.0 centipoises; WM associated glomerulonephritis or renal disease, bulky disease, or constitutional symptoms; Constitutional symptoms can be described as:; Unintentional weight loss >= 10% within the previous 6 months prior to screening; Fevers higher than 100.5 degrees Fahrenheit (F) or 38.0 degrees Celsius (C) for 2 or more weeks prior to screening without evidence of infection; Night sweats for more than 1 month prior to screening without evidence of infection; Clinically relevant fatigue which is not relieved by rest due to WM
- Participants who require ongoing use or received a moderate or strong CYP3A inducer, moderate or strong CYP3A inhibitor, P-gp inhibitor within 7 days prior to the first dose of study drug will be excluded from the study. If such participants can be safely switched to an alternative agent, then the participants will be eligible to enroll
- Participants must not have had prior systemic therapy. Prior therapy with rituximab will be allowed as long as the last rituximab dose was at least 6 months prior to registration
- Participants must be >= 18 years of age
- Participants must have history and physical exam within 28 days prior to registration
- Participants must have Zubrod performance status =< 2
- Participants must have evidence of adequate renal function, as defined by creatinine clearance (CrCl) >= 30 mL/min. Values must be obtained within 14 days prior to registration
- Total bilirubin =< 1.5 x IULN (institutional upper limit of the norm) (within 14 days prior to registration)
- Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 3 x IULN (within 14 days prior to registration)
- Alkaline phosphatase =< 3 x IULN (within 14 days prior to registration)
- Platelet count >= 50,000 cells/mm\^3 (within 14 days prior to registration); NOTE: Transfusion and/or growth factor support is allowed up to 7 days prior to registration
- Hemoglobin >= 7.0 g/dL (within 14 days prior to registration); NOTE: Transfusion and/or growth factor support is allowed up to 7 days prior to registration
- Absolute neutrophil count (ANC) >= 1,000 cells/mm\^3 (within 14 days prior to registration); NOTE: Transfusion and/or growth factor support is allowed up to 7 days prior to registration
- Participants with known human immunodeficiency virus (HIV)-infection are eligible providing they are on effective anti-retroviral therapy and have undetectable viral load at their most recent viral load test and within 6 months prior to registration
- Participants must be able to take and swallow oral medication (capsules) whole. Participants may not have any known impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of the study drug (e.g. ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)
- Participants must not be intolerant to rituximab
- Participants must not have known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding localized skin and nail bed fungal infections) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) 4 weeks prior to registration
- Participants must not be seropositive for hepatitis C (except in the setting of sustained virologic response, defined as undetectable viral load at least 12 weeks after completion of antiviral therapy). Hepatitis C virus (HCV) testing is only required if clinically indicated or if the participant has a history of HCV
- Participants must not consume grapefruit, Seville oranges or starfruit within 3 days prior to the first dose of venetoclax
- Participants must not be pregnant or nursing because venetoclax has not been studied in pregnant or nursing women and the mechanism of action is expected to cause fetal harm. A woman is considered to be of "reproductive potential" if she has had menses at any time in the preceding 12 consecutive months. In addition to routine contraceptive methods, "effective contraception" e.g., implants, injectables, combined oral contraceptives, some intrauterine devices [IUDs], complete abstinence, or sterilized partner) and a barrier method (e.g., condom, cervical ring, sponge, etc.). This also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation. However, if at any point a previously celibate participant chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures throughout the study and for at least 30 days after competition of therapy
- No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the participant is currently in complete remission, or any other cancer from which the participant has been disease free for two years or watchful waiting is appropriate in the opinion of the treating physician. Also, malignancy that in the opinion of the investigator, is considered cured with minimal risk of recurrence within 5 years, is permissible consideration of eligibility for this trial
- Participants must be offered the opportunity to participate in specimen banking
- Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines. For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations
- As a part of the Oncology Participant Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
- CROSSOVER CRITERIA: Participants must have been registered and received treatment in the IR/Z or VR arm and must show progression of disease at any time during cycles 3-24
- CROSSOVER CRITERIA: In case of transformation to intermediate or high-grade lymphoma or development of Bing-Neel syndrome the participants will not undergo registration step 2 crossover and will be taken off the study
- CROSSOVER CRITERIA: Participants must have Zubrod performance status =< 2
- CROSSOVER CRITERIA: Participants must have evidence of adequate renal function, as defined by creatinine clearance (CrCl) >= 30 mL/min. Values must be obtained within 14 days prior to registration
- CROSSOVER CRITERIA: Participants must have no evidence of marked hepatic dysfunction on any recent liver function tests within 14 days prior to registration
- CROSSOVER CRITERIA: Platelet count >= 50,000 cells/mm\^3 (without within 14 days prior to registration); NOTE: Transfusion and/or growth factor support is allowed up to 7 days prior to registration
- CROSSOVER CRITERIA: Hemoglobin >= 7.0 g/dL (without within 14 days prior to registration); NOTE: Transfusion and/or growth factor support is allowed up to 7 days prior to registration
- CROSSOVER CRITERIA: Absolute neutrophil count (ANC) >= 1,000 cells/mm\^3 (without within 14 days prior to registration); NOTE: Transfusion and/or growth factor support is allowed up to 7 days prior to registration
Where in United States
- Mary Greeley Medical CenterAmes, United StatesContact: Joseph J. Merchant (principal investigator)Taking people
- McFarland Clinic - AmesAmes, United StatesContact: Joseph J. Merchant (principal investigator)Taking people
- Trinity Health Saint Joseph Mercy Hospital Ann ArborAnn Arbor, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
- ThedaCare Regional Cancer CenterAppleton, United StatesContact: Yazhini Vallatharasu (principal investigator)Taking people
- Saint Alphonsus Cancer Care Center-Baker CityBaker City, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
- Memorial Sloan Kettering Basking RidgeBasking Ridge, United StatesContact: Maria L. Palomba (principal investigator)Taking people
- Strecker Cancer Center-BelpreBelpre, United StatesNo longer taking part
- Saint Vincent Frontier Cancer CenterBillings, United StatesContact: Patrick W. Cobb (principal investigator)Taking people
- Saint Alphonsus Cancer Care Center-BoiseBoise, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
- McFarland Clinic - BooneBoone, United StatesNo longer taking part
- Trinity Health IHA Medical Group Hematology Oncology - BrightonBrighton, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
- Trinity Health Medical Center - BrightonBrighton, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
- Henry Ford Cancer Institute-DownriverBrownstown, United StatesContact: Vijayalakshmi Donthireddy (principal investigator)Taking people
- Lahey ClinicBurlington, United StatesContact: Julio Hajdenberg (principal investigator)Taking people
- Saint Alphonsus Cancer Care Center-CaldwellCaldwell, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
- Trinity Health IHA Medical Group Hematology Oncology - CantonCanton, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
- Trinity Health Medical Center - CantonCanton, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
- Saint Francis Medical CenterCape Girardeau, United StatesContact: Bryan A. Faller (principal investigator)Taking people
- Centralia Oncology ClinicCentralia, United StatesContact: Bryan A. Faller (principal investigator)Taking people
- Carolinas Medical Center/Levine Cancer InstituteCharlotte, United StatesContact: Manisha Bhutani (principal investigator)Taking people
- Chelsea HospitalChelsea, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea HospitalChelsea, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
- Adena Regional Medical CenterChillicothe, United StatesNo longer taking part
- Siteman Cancer Center at Saint Peters HospitalCity of Saint Peters, United StatesNo longer taking part
- Providence Cancer Institute Clackamas ClinicClackamas, United StatesNo longer taking part
- Hematology Oncology Consultants-ClarkstonClarkston, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
- Newland Medical Associates-ClarkstonClarkston, United StatesNo longer taking part
- Southeastern Medical Oncology Center-ClintonClinton, United StatesContact: Samer S. Kasbari (principal investigator)Taking people
- Henry Ford Macomb Hospital-Clinton TownshipClinton Township, United StatesContact: Vijayalakshmi Donthireddy (principal investigator)Taking people
- Columbus Oncology and Hematology Associates IncColumbus, United StatesNo longer taking part
- Doctors HospitalColumbus, United StatesNo longer taking part
- Grant Medical CenterColumbus, United StatesNo longer taking part
- Mount Carmel East HospitalColumbus, United StatesNo longer taking part
- Mount Carmel Health Center WestColumbus, United StatesNo longer taking part
- Riverside Methodist HospitalColumbus, United StatesNo longer taking part
- The Mark H Zangmeister CenterColumbus, United StatesNo longer taking part
- Memorial Sloan Kettering CommackCommack, United StatesContact: Maria L. Palomba (principal investigator)Taking people
- Mercy HospitalCoon Rapids, United StatesContact: David M. King (principal investigator)Taking people
- UM Sylvester Comprehensive Cancer Center at Coral GablesCoral Gables, United StatesContact: Georgios Pongas (principal investigator)Taking people
- UM Sylvester Comprehensive Cancer Center at Coral SpringsCoral Springs, United StatesContact: Georgios Pongas (principal investigator)Taking people
- Siteman Cancer Center at West County HospitalCreve Coeur, United StatesNo longer taking part
- Carle at The RiverfrontDanville, United StatesContact: Priyank P. Patel (principal investigator)Taking people
- Henry Ford Medical Center-FairlaneDearborn, United StatesContact: Vijayalakshmi Donthireddy (principal investigator)Taking people
- Cancer Care Specialists of Illinois - DecaturDecatur, United StatesContact: Bryan A. Faller (principal investigator)Taking people
- UM Sylvester Comprehensive Cancer Center at Deerfield BeachDeerfield Beach, United StatesContact: Georgios Pongas (principal investigator)Taking people
- Delaware Health Center-Grady Cancer CenterDelaware, United StatesNo longer taking part
- Grady Memorial HospitalDelaware, United StatesNo longer taking part
- Henry Ford HospitalDetroit, United StatesContact: Vijayalakshmi Donthireddy (principal investigator)Taking people
- Wayne State University/Karmanos Cancer InstituteDetroit, United StatesContact: Andrew Kin (principal investigator)Taking people
- UM Sylvester Comprehensive Cancer Center at DoralDoral, United StatesContact: Georgios Pongas (principal investigator)Taking people
- Dublin Methodist HospitalDublin, United StatesNo longer taking part
- Marshfield Medical Center-EC Cancer CenterEau Claire, United StatesNo longer taking part
- Minnesota Oncology - EdinaEdina, United StatesContact: David M. King (principal investigator)Taking people
- Swedish Cancer Institute-EdmondsEdmonds, United StatesContact: Charles W. Drescher (principal investigator)Taking people
- Carle Physician Group-EffinghamEffingham, United StatesContact: Priyank P. Patel (principal investigator)Taking people
- Crossroads Cancer CenterEffingham, United StatesContact: Bryan A. Faller (principal investigator)Taking people
- Weisberg Cancer Treatment CenterFarmington Hills, United StatesContact: Andrew Kin (principal investigator)Taking people
- Cancer Hematology Centers - FlintFlint, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
- Genesys Hurley Cancer InstituteFlint, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
- Hurley Medical CenterFlint, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
- Genesee Hematology Oncology PCFlint, United StatesNo longer taking part
- McFarland Clinic - Trinity Cancer CenterFort Dodge, United StatesContact: Joseph J. Merchant (principal investigator)Taking people
- Central Ohio Breast and Endocrine SurgeryGahanna, United StatesNo longer taking part
- Levine Cancer Institute-GastonGastonia, United StatesContact: Manisha Bhutani (principal investigator)Taking people
- Glens Falls HospitalGlens Falls, United StatesNo longer taking part
- Southeastern Medical Oncology Center-GoldsboroGoldsboro, United StatesContact: Samer S. Kasbari (principal investigator)Taking people
- Mount Carmel Grove City HospitalGrove City, United StatesNo longer taking part
- Memorial Sloan Kettering WestchesterHarrison, United StatesContact: Maria L. Palomba (principal investigator)Taking people
- UM Sylvester Comprehensive Cancer Center at HollywoodHollywood, United StatesContact: Georgios Pongas (principal investigator)Taking people
- City of Hope at Irvine LennarIrvine, United StatesContact: Benjamin M. Heyman (principal investigator)Taking people
- Swedish Cancer Institute-IssaquahIssaquah, United StatesContact: Charles W. Drescher (principal investigator)Taking people
- Allegiance HealthJackson, United StatesContact: Vijayalakshmi Donthireddy (principal investigator)Taking people
- Mayo Clinic in FloridaJacksonville, United StatesContact: Sikander Ailawadhi (principal investigator)Taking people
- Southeastern Medical Oncology Center-JacksonvilleJacksonville, United StatesContact: Samer S. Kasbari (principal investigator)Taking people
- McFarland Clinic - JeffersonJefferson, United StatesNo longer taking part
- Gundersen Lutheran Medical CenterLa Crosse, United StatesContact: David E. Marinier (principal investigator)Taking people
- Fairfield Medical CenterLancaster, United StatesNo longer taking part
- University of Michigan Health - Sparrow LansingLansing, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
- Saint Rita's Medical CenterLima, United StatesNo longer taking part
- Trinity Health Saint Mary Mercy Livonia HospitalLivonia, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
- OhioHealth Mansfield HospitalMansfield, United StatesNo longer taking part
- Marietta Memorial HospitalMarietta, United StatesNo longer taking part
- OhioHealth Marion General HospitalMarion, United StatesNo longer taking part
- McFarland Clinic - MarshalltownMarshalltown, United StatesContact: Joseph J. Merchant (principal investigator)Taking people
- Marshfield Medical Center-MarshfieldMarshfield, United StatesNo longer taking part
- Carle Physician Group-Mattoon/CharlestonMattoon, United StatesContact: Priyank P. Patel (principal investigator)Taking people
- Loyola University Medical CenterMaywood, United StatesContact: Patrick A. Hagen (principal investigator)Taking people
- Idaho Urologic Institute-MeridianMeridian, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
- UM Sylvester Comprehensive Cancer Center at KendallMiami, United StatesContact: Georgios Pongas (principal investigator)Taking people
- University of Miami Miller School of Medicine-Sylvester Cancer CenterMiami, United StatesContact: Georgios Pongas (principal investigator)Taking people
- Memorial Sloan Kettering MonmouthMiddletown, United StatesContact: Maria L. Palomba (principal investigator)Taking people
- Abbott-Northwestern HospitalMinneapolis, United StatesContact: David M. King (principal investigator)Taking people
- Hennepin County Medical CenterMinneapolis, United StatesContact: David M. King (principal investigator)Taking people
- Marshfield Medical Center - MinocquaMinocqua, United StatesNo longer taking part
- Atrium Health Union/LCI-UnionMonroe, United StatesContact: Manisha Bhutani (principal investigator)Taking people
- Memorial Sloan Kettering BergenMontvale, United StatesContact: Maria L. Palomba (principal investigator)Taking people
- Knox Community HospitalMount Vernon, United StatesNo longer taking part
- Saint Alphonsus Cancer Care Center-NampaNampa, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
- Memorial Sloan-Kettering Cancer CenterNew York, United StatesContact: Maria L. Palomba (principal investigator)Taking people
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer CenterNew York, United StatesNo longer taking part
- Licking Memorial HospitalNewark, United StatesContact: Aruna C. Gowda (principal investigator)Taking people
- Newark Radiation OncologyNewark, United StatesNo longer taking part
- Providence Newberg Medical CenterNewberg, United StatesContact: Charles W. Drescher (principal investigator)Taking people
- University of Miami Sylvester Comprehensive Cancer Center at Sole MiaNorth Miami, United StatesContact: Georgios Pongas (principal investigator)Taking people
- Henry Ford Medical Center-ColumbusNovi, United StatesContact: Vijayalakshmi Donthireddy (principal investigator)Taking people
- Cancer Care Center of O'FallonO'Fallon, United StatesContact: Bryan A. Faller (principal investigator)Taking people
- Saint Alphonsus Cancer Care Center-OntarioOntario, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
- Providence Willamette Falls Medical CenterOregon City, United StatesContact: Charles W. Drescher (principal investigator)Taking people
- Mercy Health - Perrysburg HospitalPerrysburg, United StatesNo longer taking part
- UM Sylvester Comprehensive Cancer Center at PlantationPlantation, United StatesContact: Georgios Pongas (principal investigator)Taking people
- Michigan Healthcare Professionals PontiacPontiac, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
- Trinity Health IHA Medical Group-Alice Gustafson CenterPontiac, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
- Trinity Health Saint Joseph Mercy Oakland HospitalPontiac, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
- Providence Portland Medical CenterPortland, United StatesContact: Charles W. Drescher (principal investigator)Taking people
- Providence Saint Vincent Medical CenterPortland, United StatesContact: Charles W. Drescher (principal investigator)Taking people
- Southern Ohio Medical CenterPortsmouth, United StatesNo longer taking part
- Marshfield Medical Center-Rice LakeRice Lake, United StatesNo longer taking part
- VCU Massey Comprehensive Cancer CenterRichmond, United StatesContact: Bharadhwaj Kolipakkam (principal investigator)Taking people
- Mayo Clinic in RochesterRochester, United StatesContact: Sikander Ailawadhi (principal investigator)Taking people
- University of RochesterRochester, United StatesContact: Clive S. Zent (principal investigator)Taking people
- MyMichigan Medical Center SaginawSaginaw, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
- Oncology Hematology Associates of Saginaw Valley PCSaginaw, United StatesNo longer taking part
- Heartland Regional Medical CenterSaint Joseph, United StatesContact: Jay W. Carlson (principal investigator)Taking people
- Park Nicollet Clinic - Saint Louis ParkSaint Louis Park, United StatesContact: David M. King (principal investigator)Taking people
- Regions HospitalSaint Paul, United StatesContact: David M. King (principal investigator)Taking people
- United HospitalSaint Paul, United StatesContact: David M. King (principal investigator)Taking people
- Swedish Medical Center-First HillSeattle, United StatesContact: Charles W. Drescher (principal investigator)Taking people
- Southern Illinois University School of MedicineSpringfield, United StatesContact: Bryan A. Faller (principal investigator)Taking people
- Springfield ClinicSpringfield, United StatesContact: Bryan A. Faller (principal investigator)Taking people
- Springfield Memorial HospitalSpringfield, United StatesContact: Bryan A. Faller (principal investigator)Taking people
- Mercy Hospital SouthSt Louis, United StatesContact: Jay W. Carlson (principal investigator)Taking people
- Siteman Cancer Center at Christian HospitalSt Louis, United StatesNo longer taking part
- Siteman Cancer Center-South CountySt Louis, United StatesNo longer taking part
- Washington University School of MedicineSt Louis, United StatesNo longer taking part
- Marshfield Medical Center-River Region at Stevens PointStevens Point, United StatesContact: Adedayo A. Onitilo (principal investigator)Taking people
- MyMichigan Medical Center TawasTawas City, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
- Mercy Health - Saint Anne HospitalToledo, United StatesNo longer taking part
- Mercy Health - Saint Vincent HospitalToledo, United StatesNo longer taking part
- Banner University Medical Center - TucsonTucson, United StatesContact: Muhammad Husnain (principal investigator)Taking people
- University of Arizona Cancer Center-North CampusTucson, United StatesContact: Muhammad Husnain (principal investigator)Taking people
- Memorial Sloan Kettering NassauUniondale, United StatesContact: Maria L. Palomba (principal investigator)Taking people
- Carle Cancer CenterUrbana, United StatesContact: Priyank P. Patel (principal investigator)Taking people
- Wilmot Cancer Institute at WebsterWebster, United StatesContact: Clive S. Zent (principal investigator)Taking people
- Henry Ford West Bloomfield HospitalWest Bloomfield, United StatesContact: Vijayalakshmi Donthireddy (principal investigator)Taking people
- Saint Ann's HospitalWesterville, United StatesNo longer taking part
- Marshfield Medical Center - WestonWeston, United StatesContact: Adedayo A. Onitilo (principal investigator)Taking people
- Henry Ford Wyandotte HospitalWyandotte, United StatesContact: Vijayalakshmi Donthireddy (principal investigator)Taking people
- Huron Gastroenterology PCYpsilanti, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor CampusYpsilanti, United StatesContact: Tareq Al baghdadi (principal investigator)Taking people
- Genesis Healthcare System Cancer Care CenterZanesville, United StatesNo longer taking part
About the trial
What the trial wants to find out
This phase II trial studies the effects of venetoclax and rituximab in comparison to ibrutinib and rituximab or zanubrutinib in treating patients with previously untreated Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Zanubrutinib, a type of tyrosine kinase inhibitor, blocks a protein called BTK, which may help keep cancer cells from growing. Giving venetoclax and rituximab may work better in treating patients with previously untreated Waldenstrom's macroglobulinemia than ibrutinib with rituximab or zanubrutinib alone.
The 2 groups in the trial
- Arm I (ibrutinib + rituximab or zanubrutinib)Existing treatment, for comparison
Patients receive ibrutinib PO QD on days 1-28 of cycles 1-24 and rituximab IV on days 1, 8, 15, and 22 of cycles 2 and 5, or zanubrutinib PO QD or BID on days 1-28 of cycles 1-24. Cycles repeat every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients with progressive disease during Arm I may receive rituximab and venetoclax as in Arm II for up to an additional 24 cycles. Patients undergo CT or PET/CT and bone marrow biopsy and aspiration as well as blood sample collection throughout the trial.
Treatment: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Ibrutinib, Positron Emission Tomography, Rituximab, and Zanubrutinib
- Arm II (venetoclax, rituximab)Treatment being tested
Patients receive venetoclax PO QD on days 1-28 of each cycle and rituximab IV on days 1, 8, 15, and 22 of cycles 2 and 5. Cycles repeat every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients with progressive disease during Arm II may receive ibrutinib and rituximab as in Arm I for up to an additional 24 cycles. Patients undergo CT or PET/CT and bone marrow biopsy and aspiration as well as blood sample collection throughout the trial.
Treatment: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Positron Emission Tomography, Rituximab, and Venetoclax
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase II Randomized Study Comparing BTK Inhibitors (Ibrutinib Plus Rituximab or Zanubrutinib Alone) vs. BCL-2 Inhibitor (Venetoclax) and Rituximab in Previously Untreated Waldenström's Macroglobulinemia (WM) / Lymphoplasmacytic Lymphoma (LPL)
- Record updated
- 12 November 2026